Propanc Biopharma Advances Assay Development for Phase 1b Cancer Study
Propanc Biopharma said it advanced bioanalytical and immunogenicity assay development for a Phase 1b first-in-human study involving up to 50 advanced cancer patients.
Propanc Biopharma said it advanced bioanalytical and immunogenicity assay development for a Phase 1b first-in-human study involving up to 50 advanced cancer patients.